Rapid growth forecast for glioblastoma multiforme therapeutics market

6 June 2014
stockmarket

According to a new report, growth in the glioblastoma multiforme (GBM) therapeutics market in major developed nations to 2019 hinges on the success of personalized vaccine, following early approval in Germany.

During the 2012-2019 forecast period, the GBM market is expected to grow rapidly from $305 million to $583 million. Due to the poor prognosis under currently available treatments, therapies with high potency are in strong demand in the GBM market.

In newly diagnosed patients, the current standard of care, comprising resection surgery, radiation therapy and chemotherapy with Merck & Co's (NYSE: MRK) Temodar (temozolomide), has a maximum overall survival (OS) of 15 months and almost inevitable tumor recurrence. Current therapeutic options for recurrent GBM are Roche's (ROG: SIX) Avastin (bevacizumab), carmustine and other chemotherapy drugs used off-label. However, they only offer limited OS benefit, leaving high unmet need in this patient segment.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical